PCRX logo

Pacira BioSciences (PCRX) Cash From Operations

Annual CFO

$154.65 M
+$9.38 M+6.45%

December 31, 2023

Summary

Performance

1-Year Change

+6.45%

3-Year Change

+100.76%

5-Year Change

+216.45%

15-Year Change

+769.55%

PCRX Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

89.14%
PCRX annual cash flow from operations is higher than 89.14% of companies in Healthcare sector

High & Low

All-time High

$154.65 M
PCRX annual cash flow from operations is currently at an all-time high

3-Year Low

$125.72 M
PCRX annual cash flow from operations is currently +23.01% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
PCRX previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Feb 28, 2025
PCRX next annual earnings announcement is scheduled for Feb 28, 2025

OtherPCRXcash flowmetrics:

Annual CFI

$77.54 M
PCRX annual cash flow from investing activities is $77.54 million

Annual CFF

-$183.03 M
PCRX annual cash flow from financing activities is -$183.03 million

Annual FCF

$139.49 M
PCRX annual free cash flow is $139.49 million

Annual CAPEX

$15.16 M
PCRX annual capital expenditures is $15.16 million

Quarterly CFO

$53.92 M
+$684.00 K+1.28%

September 30, 2024

Summary

Performance

3-Month Change

+1.28%

1-Year Change

+21.34%

3-Year Change

+75.2%

5-Year Change

+75.2%

PCRX Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

89%
PCRX quarterly cash flow from operations is higher than 89% of companies in Healthcare sector

High & Low

All-time High

$60.29 M
PCRX quarterly cash flow from operations is currently -10.56% below its historical high of $60.29 million

3-Year Low

$19.13 M
PCRX quarterly cash flow from operations is currently +181.89% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
PCRX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 28, 2025
PCRX next earnings announcement is scheduled for Feb 28, 2025

OtherPCRXcash flowmetrics:

Quarterly CFI

-$52.16 M
PCRX quarterly cash flow from investing activities is -$52.16 million

Quarterly CFF

-$2.85 M
PCRX quarterly cash flow from financing activities is -$2.85 million

Quarterly FCF

$49.83 M
PCRX quarterly free cash flow is $49.83 million

Quarterly CAPEX

$4.09 M
PCRX quarterly capital expenditures is $4.09 million

TTM CFO

$203.84 M
+$9.48 M+4.88%

September 30, 2024

Summary

Performance

3-Month Change

+4.88%

1-Year Change

+36.71%

3-Year Change

+41.15%

5-Year Change

+41.15%

PCRX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

89.96%
PCRX TTM cash flow from operations is higher than 89.96% of companies in Healthcare sector

High & Low

All-time High

$203.84 M
PCRX TTM cash flow from operations is currently at an all-time high

3-Year Low

$125.72 M
PCRX TTM cash flow from operations is currently +62.14% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
PCRX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 28, 2025
PCRX next earnings announcement is scheduled for Feb 28, 2025

OtherPCRXcash flowmetrics:

TTM CFI

-$74.53 M
PCRX TTM cash flow from investing activities is -$74.53 million

TTM CFF

$17.54 M
PCRX TTM cash flow from financing activities is $17.54 million

TTM FCF

$193.53 M
PCRX TTM free cash flow is $193.53 million

TTM CAPEX

$10.32 M
PCRX TTM capital expenditures is $10.32 million

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

PCRX Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+6.5%+21.3%+36.7%
3 y3 years+100.8%+75.2%+41.1%
5 y5 years+216.4%+75.2%+41.1%

PCRX Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+23.0%at high+181.9%at high+62.1%
5 y5-yearat high+119.3%-10.6%+445.1%at high+485.0%
alltimeall timeat high+320.5%-10.6%+354.6%at high+390.7%

Pacira BioSciences Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
$53.92 M(+1.3%)
$203.84 M(+4.9%)
Jun 2024
-
$53.24 M(+8.4%)
$194.36 M(+5.3%)
Mar 2024
-
$49.10 M(+3.2%)
$184.62 M(+19.4%)
Dec 2023
$154.65 M(+6.5%)
$47.58 M(+7.1%)
$154.65 M(+3.7%)
Sep 2023
-
$44.44 M(+2.2%)
$149.10 M(+1.2%)
Jun 2023
-
$43.50 M(+127.4%)
$147.32 M(+10.2%)
Mar 2023
-
$19.13 M(-54.5%)
$133.63 M(-8.0%)
Dec 2022
$145.27 M(+15.6%)
$42.04 M(-1.4%)
$145.27 M(+14.9%)
Sep 2022
-
$42.65 M(+43.1%)
$126.45 M(-12.2%)
Jun 2022
-
$29.81 M(-3.2%)
$144.09 M(-0.2%)
Mar 2022
-
$30.78 M(+32.6%)
$144.41 M(+14.9%)
Dec 2021
$125.72 M(+63.2%)
$23.21 M(-61.5%)
$125.72 M(-15.7%)
Sep 2021
-
$60.29 M(+100.1%)
$149.17 M(+15.9%)
Jun 2021
-
$30.13 M(+149.4%)
$128.66 M(+55.2%)
Mar 2021
-
$12.08 M(-74.1%)
$82.91 M(+7.6%)
Dec 2020
$77.03 M(+9.2%)
$46.67 M(+17.3%)
$77.03 M(+36.9%)
Sep 2020
-
$39.78 M(-354.6%)
$56.27 M(+61.5%)
Jun 2020
-
-$15.62 M(-351.7%)
$34.84 M(-52.4%)
Mar 2020
-
$6.21 M(-76.0%)
$73.23 M(+3.8%)
Dec 2019
$70.52 M(+44.3%)
$25.90 M(+41.1%)
$70.52 M(+7.1%)
Sep 2019
-
$18.35 M(-19.4%)
$65.84 M(+2.7%)
Jun 2019
-
$22.76 M(+550.6%)
$64.11 M(+16.4%)
Mar 2019
-
$3.50 M(-83.5%)
$55.06 M(+12.7%)
Dec 2018
$48.87 M(+174.8%)
$21.22 M(+27.6%)
$48.87 M(+9.6%)
Sep 2018
-
$16.63 M(+21.3%)
$44.58 M(+77.3%)
Jun 2018
-
$13.71 M(-609.9%)
$25.14 M(+66.6%)
Mar 2018
-
-$2.69 M(-115.9%)
$15.09 M(-15.2%)
Dec 2017
$17.79 M
$16.93 M(-703.0%)
$17.79 M(-2.3%)
Sep 2017
-
-$2.81 M(-176.8%)
$18.20 M(-44.3%)
Jun 2017
-
$3.66 M(>+9900.0%)
$32.70 M(-10.6%)
DateAnnualQuarterlyTTM
Mar 2017
-
$6000.00(-100.0%)
$36.58 M(+9.3%)
Dec 2016
$33.45 M(+19.4%)
$17.35 M(+48.5%)
$33.45 M(+1.1%)
Sep 2016
-
$11.68 M(+54.9%)
$33.10 M(+26.7%)
Jun 2016
-
$7.54 M(-341.6%)
$26.13 M(+1.4%)
Mar 2016
-
-$3.12 M(-118.4%)
$25.77 M(-8.0%)
Dec 2015
$28.02 M(+5.5%)
$16.99 M(+260.1%)
$28.02 M(+8.8%)
Sep 2015
-
$4.72 M(-34.3%)
$25.75 M(-12.4%)
Jun 2015
-
$7.18 M(-925.1%)
$29.39 M(-3.4%)
Mar 2015
-
-$870.00 K(-105.9%)
$30.43 M(+14.6%)
Dec 2014
$26.56 M(-160.6%)
$14.72 M(+76.1%)
$26.56 M(+437.7%)
Sep 2014
-
$8.36 M(+1.7%)
$4.94 M(-137.3%)
Jun 2014
-
$8.22 M(-273.5%)
-$13.26 M(-61.9%)
Mar 2014
-
-$4.74 M(-31.4%)
-$34.78 M(-20.7%)
Dec 2013
-$43.84 M(-37.5%)
-$6.90 M(-29.8%)
-$43.84 M(-24.6%)
Sep 2013
-
-$9.84 M(-26.1%)
-$58.12 M(-2.3%)
Jun 2013
-
-$13.31 M(-3.5%)
-$59.45 M(-10.4%)
Mar 2013
-
-$13.79 M(-34.9%)
-$66.37 M(-5.4%)
Dec 2012
-$70.13 M(+126.2%)
-$21.18 M(+89.5%)
-$70.13 M(+24.0%)
Sep 2012
-
-$11.18 M(-44.7%)
-$56.55 M(+5.0%)
Jun 2012
-
-$20.23 M(+15.3%)
-$53.86 M(+20.9%)
Mar 2012
-
-$17.55 M(+131.0%)
-$44.56 M(+43.7%)
Dec 2011
-$31.00 M(+24.6%)
-$7.60 M(-10.6%)
-$31.00 M(+6.0%)
Sep 2011
-
-$8.49 M(-22.2%)
-$29.24 M(+5.7%)
Jun 2011
-
-$10.92 M(+174.0%)
-$27.66 M(+9.5%)
Mar 2011
-
-$3.99 M(-31.7%)
-$25.27 M(+1.6%)
Dec 2010
-$24.88 M(+19.4%)
-$5.84 M(-15.5%)
-$24.88 M(+30.7%)
Sep 2010
-
-$6.91 M(-19.0%)
-$19.04 M(+57.0%)
Jun 2010
-
-$8.53 M(+137.2%)
-$12.13 M(+237.2%)
Mar 2010
-
-$3.60 M
-$3.60 M
Dec 2009
-$20.84 M(-28.6%)
-
-
Dec 2008
-$29.19 M
-
-

FAQ

  • What is Pacira BioSciences annual cash flow from operations?
  • What is the all time high annual CFO for Pacira BioSciences?
  • What is Pacira BioSciences annual CFO year-on-year change?
  • What is Pacira BioSciences quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Pacira BioSciences?
  • What is Pacira BioSciences quarterly CFO year-on-year change?
  • What is Pacira BioSciences TTM cash flow from operations?
  • What is the all time high TTM CFO for Pacira BioSciences?
  • What is Pacira BioSciences TTM CFO year-on-year change?

What is Pacira BioSciences annual cash flow from operations?

The current annual CFO of PCRX is $154.65 M

What is the all time high annual CFO for Pacira BioSciences?

Pacira BioSciences all-time high annual cash flow from operations is $154.65 M

What is Pacira BioSciences annual CFO year-on-year change?

Over the past year, PCRX annual cash flow from operations has changed by +$9.38 M (+6.45%)

What is Pacira BioSciences quarterly cash flow from operations?

The current quarterly CFO of PCRX is $53.92 M

What is the all time high quarterly CFO for Pacira BioSciences?

Pacira BioSciences all-time high quarterly cash flow from operations is $60.29 M

What is Pacira BioSciences quarterly CFO year-on-year change?

Over the past year, PCRX quarterly cash flow from operations has changed by +$9.48 M (+21.34%)

What is Pacira BioSciences TTM cash flow from operations?

The current TTM CFO of PCRX is $203.84 M

What is the all time high TTM CFO for Pacira BioSciences?

Pacira BioSciences all-time high TTM cash flow from operations is $203.84 M

What is Pacira BioSciences TTM CFO year-on-year change?

Over the past year, PCRX TTM cash flow from operations has changed by +$54.74 M (+36.71%)